EDITORIAL
Published on 09 Sep 2022
Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?
doi 10.3389/fonc.2022.1020185
- 1,042 views
- 1 citation
- Frontiers in Oncology
- Hematologic Malignancies
- Research Topics
- Acute Myeloid Leukemia (AML): Is it time for MRD-driven treatment?
Acute Myeloid Leukemia (AML): Is it time for MRD-driven treatment?
6,850
Total downloads
19k
Total views and downloads
Submit your idea
You will be redirected to our submission process.
Articles
REVIEW
Published on 18 Jul 2022
MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
doi 10.3389/fonc.2022.890871
- 4,639 views
- 3 citations
ORIGINAL RESEARCH
Published on 08 Apr 2022
Leukemia Stem Cell Frequency at Diagnosis Correlates With Measurable/Minimal Residual Disease and Impacts Survival in Adult Acute Myeloid Leukemia
doi 10.3389/fonc.2022.867684
- 2,836 views
- 5 citations
REVIEW
Published on 17 Feb 2022
Analysis of Subset Chimerism for MRD-Detection and Pre-Emptive Treatment in AML
doi 10.3389/fonc.2022.841608
- 3,058 views
- 8 citations
ORIGINAL RESEARCH
Published on 06 Jan 2022
Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
doi 10.3389/fonc.2021.773394
- 2,195 views
- 13 citations
ORIGINAL RESEARCH
Published on 20 May 2021
Measurable Residual Disease Detected by Multiparameter Flow Cytometry and Sequencing Improves Prediction of Relapse and Survival in Acute Myeloid Leukemia
doi 10.3389/fonc.2021.677833
- 2,622 views
- 7 citations
Published in
Frontiers in Oncology
- Hematologic Malignancies
Impact
- 19kTopic views
- 12kArticle views
- 6,850Article downloads